SynthesisSystematic reviews2026
Efficacy and safety of neoadjuvant targeted therapy in non-small cell lung cancer: a systematic review and meta-analysis.
Synthesis in Systematic reviews, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
introductionEpidermal growth factor receptor (EGFR) mutations are major oncogenic drivers in non-small cell lung cancer (NSCLC), occurring in 30-50% of Asian patients. Neoadjuvant EGFR-tyrosine kinase inhibitors (EGFR-TKIs) may improve surgical outcomes in resectable EGFR-mutant NSCLC, but evidence from small, heterogeneous trials is inconsistent and the overall efficacy and safety remain unclear.
objectivesTo evaluate the efficacy and safety of neoadjuvant EGFR-TKI monotherapy in sensitizing EGFR-mutant NSCLC.
methodsPubMed, Embase, the Cochrane Library, and Web of Science were searched from inception to June 30, 2025. Prospective studies of neoadjuvant EGFR-TKI monotherapy in adults with genetically confirmed sensitizing EGFR-mutant NSCLC were eligible. Two investigators independently extracted data. Heterogeneity was assessed using Cochran's Q test and the I
resultsFifteen prospective studies involving 452 patients were included. The pooled ORR was 0.61 (95% confidence interval [CI] 0.54-0.67). The incidence of grade ≥ 3 AEs was 0.11 (95% CI 0.08-0.15), indicating an acceptable safety profile. The pooled MPR and pCR rates were 0.21 (95% CI 0.15-0.29) and 0.11 (95% CI 0.08-0.15), respectively. The pooled R0 resection rate was 0.90 (95% CI 0.86-0.94). ORR was higher in patients aged ≥ 60 years than < 60 years (0.69 vs 0.54, P = 0.01). pCR was higher in Chinese than non-Chinese patients (0.10 vs 0.03, P = 0.04).
conclusionNeoadjuvant EGFR-TKI monotherapy was associated with promising efficacy and a manageable safety profile in stage I-III EGFR-mutant NSCLC patients. However, the evidence is derived predominantly from single-arm prospective studies, limiting inference regarding comparative efficacy and survival benefit. Large randomized controlled trials with long-term follow-up are needed to confirm these findings. SYSTEMATIC REVIEW REGISTRATION: PROSPERO CRD420251064957.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.